A recent study posted to the medRxiv* preprint server evaluated the molecular and histopathological effects in the placenta following a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during pregnancy.
Study: Gestational SARS-CoV-2 infection is associated with placental expression of immune and trophoblast genes. Image Credit: fizkes/Shutterstock
Background
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
The coronavirus disease 2019 (COVID-19) pandemic has caused more than 435 million infections to date globally. COVID-19 infection results in many clinical manifestations, from asymptomatic disease to complex multisystem organ failure and death in critical cases.
The immune system of females during pregnancy undergoes dynamic changes promoting fetal tolerance. According to some studies, pregnant females with severe COVID-19 are at a higher risk of admission to intensive care unit (ICU), extracorporeal membrane oxygenation, mechanical ventilation, and mortality than non-pregnant individuals. Another study reported that active COVID-19 infection at delivery is associated with neonatal and obstetric complications.
SARS-CoV-2 uses the host angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane protease serine 2 (TMPRSS2) to enter host cells. During pregnancy, placental syncytiotrophoblast and cytotrophoblast cells express ACE2 and TMPRSS2. However, vertical transmission of SARS-CoV-2 to the fetus is rare, with just a few reports of SARS-CoV-2 in fetal compartments of the placenta and newborns.
The study
In the present study, researchers evaluated placentas delivered from SARS-CoV-2 IgG-positive individuals for histopathological and gene expression changes, comparing them with IgG negative pregnant individuals.
The study participants were recruited as part of the Generation C study, a prospective pregnancy cohort study examining the effects of COVID-19 during pregnancy. Maternal blood specimens were obtained at different time points, their electronic medical records were reviewed, and IgG serological tests were utilized to confirm COVID-19 history. Enzyme-linked immunosorbent assay (ELISA) tests detected anti-spike (anti-S) IgG for serological examination. Placental samples were retrieved post-delivery, and histopathological examination was performed per standard protocol.
Ribonucleic acid (RNA) was isolated from formaldehyde-fixed paraffin-embedded (FFPE) tissue blocks, and its concentration was measured using Nanodrop. Gene expression was analyzed with NanoString codeset panel with 50 probes that included stress response genes, immune or inflammatory response genes, SARS-CoV-2-response host genes, SARS-CoV-2 nucleocapsid (N), and envelope (E) genes, among others.
Results
About 45 participants from the Generation C study were included, of which 15 were IgG positive, and 30 were IgG negative. Two IgG-positive subjects were SARS-CoV-2 positive at the time of delivery admission. The median gestational age of the IgG serological test was 35 weeks. All deliveries were live births, with 37 at term and eight at preterm. No differences were observed in gestational periods between the study groups, with a median gestational age of around 39 weeks for neonates at the time of delivery. In the negative IgG cohort, 66.7% of newborns were males compared to 33.3% in the positive IgG cohort.
For gene expression profiling, 44 samples, 29 from IgG negative group and 15 from IgG positive participants, were analyzed for 48 genes. Nine genes were removed from differential gene expression analysis because they were below the background level in both cohorts. These were host cell entry genes like TMPRSS2 and ACE2, stress and immune response genes such as IL17A, IFNL3, IL23A, IFNA1, ORPM1, and SARS-CoV-2’s N and E genes. Three genes were associated with IgG serological status when the SARS-CoV-2 IgG status was adjusted for covariates.
The authors noted that the trophoblast cell marker genes CGB3 and PSG3 were downregulated, and CXCL10 was overexpressed compared to the IgG-negative participants. When the gene expression analysis was adjusted for cell-type proxies and covariates, IgG positive state was correlated with increased CXCL10, DDX58, and TLR3 genes.
Conclusions
The current study evaluated the effects of a COVID-19 infection during pregnancy by assessing molecular and histopathological changes in placentas and found differences in trophoblast specific and immune response genes between IgG positive and IgG negative subjects. Placental expression of CGB3 and PSG3 were lower in IgG positive subjects relative to IgG negative participants.
PSG3 secreted during pregnancy into the mother’s circulation is implicated in angiogenic and immunoregulatory functions. CGB3 codes for the beta 3 subunit of human chorionic gonadotrophin (hCG) hormone were involved in maternal immunotolerance and angiogenesis. CXCL10, a pro-inflammatory chemokine, was higher in IgG-positive subjects. Besides, TLR3 and DDX58 genes were overexpressed in placentas from IgG-positive participants.
Although the study participants were demographically diverse, the sample size was limited, with a relatively small number of placentas from IgG-positive subjects. Also, there is no data regarding the time of COVID-19 infection, clinical severity, and serological status of the neonates. Thus, more research is required to investigate the changes of the whole placental transcriptome.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- May 11 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies